Mark Purcell
Stock Analyst at Morgan Stanley
(1.34)
# 3,639
Out of 5,104 analysts
6
Total ratings
66.67%
Success rate
-5.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Upgrades: Overweight | $56 → $58 | $48.23 | +20.26% | 2 | Sep 8, 2025 | |
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $138.54 | -17.71% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $49.63 | -11.34% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $91.57 | -7.17% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $52.39 | +129.05% | 1 | Jan 23, 2024 |
Sanofi
Sep 8, 2025
Upgrades: Overweight
Price Target: $56 → $58
Current: $48.23
Upside: +20.26%
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $138.54
Upside: -17.71%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $49.63
Upside: -11.34%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $91.57
Upside: -7.17%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $52.39
Upside: +129.05%